Inhibrx Biosciences
Update in progressINBX (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Inhibrx Biosciences, Inc. is a clinical‑stage biopharmaceutical company developing biologic therapeutics for patients with life‑threatening diseases. Its candidates include INBRX‑109 in Phase 1, a tetravalent therapy targeting death‑receptor 5 for unresectable or metastatic conventional chondrosarcoma, and INBRX‑106, a hexavalent sdAb therapy targeting OX4 for several metastatic solid tumors. Founded in 2024, based in La Jolla, California.
Company score
- Sentiment
- 0.53
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.42
- Governance
- 0.00
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.12
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.32
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!